Information Provided By:
Fly News Breaks for September 8, 2017
ALNY
Sep 8, 2017 | 07:04 EDT
Leerink analyst Paul Matteis lowered his price target for Alnylam Pharmaceuticals to $72 after removing sales from non-inhibitor patients from his valuation and reducing his odds-of-success for fitusiran in the inhibitor population to 35%. The changes follow Alnylam's announcement that dosing in the Phase 3 Atlas programs has been halted due to a fatal thrombotic event in a patient with hemophilia A without inhibitors. The analyst keeps a Market Perform rating on Alnylam.
News For ALNY From the Last 2 Days
There are no results for your query ALNY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.